Next Article in Journal
Removal of Methyl Red from Aqueous Solution Using Biochar Derived from Fennel Seeds
Previous Article in Journal
Anti-Inflammatory Ergosteroid Derivatives from the Coral-Associated Fungi Penicillium oxalicum HL-44
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 23
10.3390/molecules28237785
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes

by
Hennie Marie Johnsen
1,2,*,
Marianne Hiorth
1 and
Jo Klaveness
1
1
Department of Pharmacy, University of Oslo, Sem Sælands Vei 3, 0371 Oslo, Norway
2
Nacamed AS, Oslo Science Park, Guastadalléen 21, 0349 Oslo, Norway
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(23), 7785; https://doi.org/10.3390/molecules28237785
Submission received: 13 September 2023 / Revised: 21 November 2023 / Accepted: 23 November 2023 / Published: 26 November 2023
Browse Figures
Versions Notes

Abstract

:
With its antioxidant properties, hydrogen gas (H2) has been evaluated in vitro, in animal studies and in human studies for a broad range of therapeutic indications. A simple search of “hydrogen gas” in various medical databases resulted in more than 2000 publications related to hydrogen gas as a potential new drug substance. A parallel search in clinical trial registers also generated many hits, reflecting the diversity in ongoing clinical trials involving hydrogen therapy. This review aims to assess and discuss the current findings about hydrogen therapy in the 81 identified clinical trials and 64 scientific publications on human studies. Positive indications have been found in major disease areas including cardiovascular diseases, cancer, respiratory diseases, central nervous system disorders, infections and many more. The available administration methods, which can pose challenges due to hydrogens’ explosive hazards and low solubility, as well as possible future innovative technologies to mitigate these challenges, have been reviewed. Finally, an elaboration to discuss the findings is included with the aim of addressing the following questions: will hydrogen gas be a new drug substance in future clinical practice? If so, what might be the administration form and the clinical indications?

1. Introduction to Hydrogen Therapy

The most frequently used medical gases include medical air, oxygen, nitrogen, nitrous oxide and carbon dioxide, and hydrogen gas (H2) is a promising newcomer with unique antioxidant properties. Demonstrated to selectively counteract deleterious reactive oxygen species (ROS), such as the hydroxyl radical, H2 can maintain tissue homeostasis and can be more clinically useful than strong antioxidants that indiscriminately neutralize both beneficial and harmful ROS species [1]. Initially introduced in diving gas around 1970, H2 was thought to be non-toxic and biologically inert [2]. The interest in using H2 for disease treatment has increased since the antioxidant properties were unveiled in 2007 [3]. Since then, over 2000 scientific publications have elucidated its therapeutic promise from in vitro, in vivo animal and human studies.
The expanding body of literature substantiates therapeutic effects of H2 and clinical trials have been conducted within major disease areas like cardiovascular, respiratory and cancer, with a focus on diseases associated with the accumulation of ROS. Yet, translation into standard clinical practice presents challenges. One challenge is administration of a decent H2 dose due to its low water solubility and its explosive properties when mixed with oxygen gas (O2). Drinking H2-saturated water has been reported to be a common and feasible method but H2 has a low water solubility of 1.57 mg/L (1.57 ppm), corresponding to approximately 19 mL/L at standard ambient temperature and pressure (SATP) conditions. Therefore, to obtain several milligrams of H2 per day, the ingestion of several liters of saturated hydrogen water per day is required [4]. The injection of H2-rich saline is also limited by its low aqueous solubility and can only be performed with proper equipment, which is typically performed in selected clinics. The explosive/flammable danger limit of H2 in O2 mixtures is about 4% [2] and, surprisingly, administration by inhalation is performed both below and above this limit. H2 is the smallest molecule with a molecular weight of only 2 Da, a kinetic diameter of 289 pm [5] and a density of about 0.089 g/L [6]. Therefore, it can easily permeate biological membranes and diffuse throughout the body, including to the brain. This has been shown for all the abovementioned administration methods in biodistribution studies in rats and pigs [7,8].
Commercially, H2 is predominantly generated by electrolysis for industrial and green fuel applications. H2-enriched water, specialized machines for H2 generation and products for making H2-rich water like magnesium effervescent tablets are already being sold around the world, marketed with health benefits. The global hydrogen generation market size was valued at USD 155.35 billion in 2022 [9]. Yet, its medical utility remains a fraction of this figure.
Despite compelling evidence from animal and human studies, H2 is yet to gain universal acceptance in clinical settings. Potential hindrances encompass possible lack of regulatory documentation studies of efficacy and safety, administration intricacies, and safety concerns tied to its explosive tendencies in the presence of oxygen. Based on the increasing number of scientific publications within the field, the authors have asked the following questions:
  • Will H2 emerge as a novel drug in clinical practice?
  • Which administration form optimizes the efficacy of H2?
  • What are the potential clinical applications for H2?
These three questions form the scientific basis for the current review publication.

2. Methods

Published scientific literature related to H2 therapy was identified by specific searches using the terms “hydrogen therapy”, “medical use of hydrogen” and “hydrogen gas” in combination with “human study” and “clinical trial”, in several readily searchable publication databases including PubMed. Scientific papers written in a different language than English and those studying human effects of alkaline ionized water were excluded. An overview of the clinical trials was gathered from www.clinicaltrils.gov (accessed on 30 September 2023), the international clinical trials register by U.S. Department of Health and Human Services (National Institutes of Health, National Library of Medicine), and www.umin.ac.jp/ctr/ (accessed on 30 September 2023), the Japanese preregistration system for approved clinical trials (UMIN, University Hospital Medical Information Network). The relevant clinical trials were found by searching for “hydrogen”, “hydrogen gas” and “H2” (trials about “hydrogen peroxide” and “hydrogen breath test” were excluded). Publications related to the clinical trials were also included in the present review. This research resulted in 47 and 34 clinical trials, from cliniclatrials.gov and UMIN, respectively, and 64 publications on human studies (in addition to several relevant animal and in vitro studies). A review article published in 2015 made a summary of the clinical trials up until that year, and the present summary therefore mainly focuses on the clinical data produced in the period after [10].
This review publication is sectioned as follows. Section 3 of this review presents and discusses the quantitative data of clinical trials and publications related to H2 therapy. Section 4 discusses safety of H2 administration, which is the first important topic upon clinical translation of a novel drug. Section 5 includes a tabular overview of the clinical trials registered at clinicaltrials.gov and UMIN and discusses the findings there. Section 6 qualitatively investigates the data from published reports after human studies, including clinical trials, by describing the study methodology and the main findings. These results formed the basis for the discussion in Section 7.

3. Quantitative Overview of Clinical Trials and Scientific Publications

A quantitative overview of the number of clinical trials and scientific publications about H2 therapy in humans are shown as a function of the publication year, and the first publication date for the clinical trials, in Figure 1. The number of clinical trials has increased from one registered in 2011, five in 2015, with a boost to ten in 2016 and 12 in 2019, to 6–10 each year in the period 2020–2023. The number of scientific publications does not follow the same trend and has been more stable over the period 2012–2022 (data only until August 2023), with an average of approximately five publications per year, and a maximum of 11 publications in 2019. The increased publication activity during 2019–2020 can possibly be explained by the high number of clinical trials initiated in 2016 and the sudden interest in hydrogen therapy in COVID-19 studies. Therefore, the high number of clinical trials registered from 2019 to 2023 might result in a subsequent upswing in the number of scientific publications in the near future.
The publications and clinical trials sorted after the indication area and administration route are shown in Figure 2. The major disease areas globally are represented in this graph, including central nervous system (CNS), cancer, cardiovascular and respiratory. Lifestyle-related conditions also have a high number of both trials and publications, and this area is becoming increasingly important with a global population on average increasing in age and weight. Inhalation is the dominating administration method, followed by drinking H2-enriched water, infusion of H2-enriched saline. H2-bath/eye-drops and H2-dialysis have also been used in a few trials.

4. Human Safety of H2 Administration

Ensuring safety is the foremost consideration when the aim is clinical translation of a new drug substance. As opposed to other medical gases like carbon dioxide, nitric oxide, and hydrogen sulfide, H2 does not bind to hemoglobin in the bloodstream, thus H2 will not induce heme-related toxic effects. Extensive animal studies have shown that H2 administration is safe, yet comprehensive documentation of human safety across diverse administration methods remains to be demonstrated. A mixture of H2:O2 or H2:O2:He gas has been employed by deep-sea divers to prevent decompression sickness for a long time, therefore also confirming human safety of H2 inhalation. Two studies from 1988 and 1994 concluded that breathing mixtures comprising 49–56% H2 during dives to 450–500 m below sea level can alleviate some symptoms of the high-pressure nervous syndrome and confirmed the safety in use [11,12]. Notably, recent clinical studies aim to document human safety of H2 therapy, for instance the clinical studies NCT04046211 and UMIN000013221 (Table 1 and Table 2). One study involving ten cerebral ischemia patients demonstrated that inhaling 3% H2 for 30 min did not change any physiological parameters, reaffirming safety. Additionally, an increase in H2 blood levels, equivalent to findings in animal studies, was observed. However, some inconsistencies in the H2 levels between the individuals were also observed [13]. The high number of the clinical trials conducted (Table 1 and Table 2) underpins the safety and the nearly absent toxicity of H2 administration by drinking H2-saturated water, inhaling H2 gas of different levels, injection of H2-rich saline and other methods such as topical application and dialysis. Very few adverse reactions from human H2 consumption have emerged across the reported clinical studies, and all trials have concluded that H2 administration is safe for humans. Still, concerns about H2 flammability warrant continued consideration.

5. Overview of Registered Clinical Trials with H2 Administration

Once the safety of H2 administration is confirmed, the subsequent objective is to document the therapeutic efficacy of a novel drug substance, a prerequisite for its integration into everyday clinical practice. Unlike conventional medications typically evaluated for specific diseases, H2, as an antioxidant, can offer versatile application across various medical conditions. An overview of the 47 clinical trials registered at clinicaltrials.gov and 34 clinical trials registered in the UMIN database investigating hydrogen therapy is tabulated in Table 1 and Table 2, respectively (as of August 2023). The tables are sorted after disease area and administration method. Many of the listed trials are within large disease groups like cardiovascular, CNS, respiratory and cancer.
These encompass the major healthcare challenges of today demanding innovative pharmaceutical interventions. Successful outcomes of these trials bear the potential to significantly contribute to addressing the foremost sources of disease and mortality within the present global landscape [14].
A few different technological solutions have been employed to facilitate H2 administration in the clinical trials tabulated above. This includes inhalation machines that aim to make the mixture of H2 and O2 safer and more manageable. A hydrogen-oxygen generator device developed by Shanghai Asclepius Meditech Inc. (Shanghai, China) has been used for the inhalation of a gas mixture of 66% H2 and 33% O2 (3 L/min, model AMS-H-03). This technology was used in several trials for COVID-19, cancer, respiratory and cardiovascular diseases, where many of which Shanghai Asclepius Meditec Inc. was the responsible party or sponsor. Similarly, Qingdao Haizhisheng Corp. (Qingdao, China) has introduced a hydrogen generator (model HZS-2700A) delivering a flow rate of 2 L/min, which was employed in a type 2 diabetes trial. Additionally, investigations have explored the inhalation of lower H2 concentrations, typically around 2%. A Japanese company, Doctors Man Co., Ltd. (Yokohama, Japan), provides products for H2 administration such as H2 water generators and gas inhalers.
Several suppliers of products related to H2-rich water consumption have also been identified in the compiled clinical trials. Notably, electrolyzed water or magnesium (Mg) tablets that produce H2 from reaction with water, said to give concentrations of 2 ppm (2 mg/L) H2 and above, are widely used with intake of typically 0.5–1 L/day. DrinkHRW (New Westminster, Canada) is one supplier of Mg tablets and Nihon Trim Co., Ltd. (Osaka, Japan) is a supplier of electrolyzed water. Oral administration is one of the easiest to implement for self-administration at home. Moreover, suppliers of ready-to-drink H2-rich water used in clinical trials include Rejuvenation, HRW Natural Health Products Inc. (New Westminster, BC, Canada), Aquastamina-R, Nutristamina (Ostrava, Czech Republic and Melodian Co., Ltd. (Osaka, Japan). Some claim to have achieved H2 concentrations of over 7 ppm (7 mg/L) in 500 mL of water and 15 ppm (15 mg/L) in 250 mL of water [15]. Another company, HoHo Biotech (Taipei, Taiwan), has developed capsules of porous coral material that they claim can absorb and carry hydrogen. Administered orally, the nanoscale carrier can release the enclosed H2 within the body [16]. This technology has been applied in trials involving patients with rheumatologic conditions [17].
The commercial interest in developing technologies for H2 administration and the geographical diversity of clinical trials show an excitement for H2 therapy spreading across continents. Predominantly, these trials are conducted in Europe, USA and Asia. A major part of the reported clinical trials has been conducted in Japan (Table 2); however, China also emerges as a center for many of the trials, particularly those related to COVID-19. Notably, the exercise-related studies are conducted in Serbia and Czech Republic.

6. Efficacy Results of H2 Administration in Human Studies

An overview of the conducted and to-be conducted clinical trials in a certain therapeutic field, such as the one provided above, can say something about the interest in the field, however it does not consider the outcomes. The efficacy of H2 administration has been reported in at least 64 referee reviewed scientific publications that are qualitatively discussed below; many but not all are results of the clinical trials listed above. In the following presentation, the articles are categorized into sections according to the primary disease areas investigated. These categories encompass cardiovascular, cancer, respiratory, CNS, infections, lifestyle-related and other diseases, and quantitatively discuss the findings from human studies.

6.1. Cardiovascular Diseases

Cardiovascular diseases are the leading cause of deaths worldwide [14], and by such are in need of new therapies. Several clinical studies have concluded that H2 inhalation or drinking can improve the outcomes of cardiovascular diseases, most in combination with standard treatments. An early phase/initial clinical trial assessed the effect of inhaling 2% H2 gas, in combination with target temperature management, in a total of ten patients with post-cardiac arrest syndrome. H2 inhalation was found to maintain a favorable neurological outcome in patients, even though improvements were not statistically significant. However, the 90-day survival rate was significantly better in the H2-group, compared to control [18]. In another study involving five post-cardiac arrest syndrome patients given the same treatment as above, arterial H2 concentration was measurable and indications of reduced amounts of oxidative stress and cytokine levels were found [19]. A slightly larger study including 20 patients found health-promoting effects of hydrogen therapy for adverse left ventricular remodeling after percutaneous coronary intervention for patients after myocardial infarction. At the 6-month follow-up after initiating treatment with 1.3% H2 inhalation, the improvement in the left ventricular stroke volume index and ejection fraction was numerically greater than in the control group, even though the latter was not significant. Indications were given for initiating a large-scale efficacy trial [20]. H2 has also been shown as a useful modulator of blood vessel function. Flow-mediated dilation was significantly improved for patients who drank H2-rich water (7 ppm = 7 mg/L), compared to placebo [21]. These studies show that the inhalation of a low concentration H2-containing gas and drinking of H2-rich water can be useful in treating cardiac and vascular conditions, respectively.

6.2. Cancer

Cancer is the second leading cause of death in the world today [14]. H2 has been administered to cancer patients with the purpose of controlling tumor progression, for combination treatment and to alleviate side-effects and adverse events of standard cancer treatment in a variety of cancer diseases. Additionally, H2 administration has been shown to promote antitumor immune responses. Figure 3 summarizes the benefits of hydrogen therapy in cancer patients.
Two separate case studies with cancer patients with multiple metastases have shown tremendous effects of H2 inhalation therapy. One of the patients suffered from recurrent gallbladder carcinoma and was given daily H2 inhalation therapy. In the first month, the tumors continued to progress following a gradual decrease in tumor size and tumor marker levels that eventually returned to normal. After around two and a half months, the patient could resume normal life and survival was reported still after 10 months. A pseudo-progressive remission after H2 therapy was observed, which may resemble the pattern that occurs following PD-1 antibody treatment. This suggests that H2 can affect the immune system [22,23]. The other case report was a non-small cell lung cancer patient that underwent H2 gas inhalation as monotherapy after oral and surgical treatments had stabilized the first lesions. The brain metastases reduced in size after four months of H2 treatment and completely disappeared after one year. The liver and lung metastases were also stabilized after one year, and survival was lengthened [24]. These case studies are tremendous observations and show that H2 might elicit significant control of tumors after standard cancer treatments have failed. However, it does not empirically prove that H2 has medical effects in cancer patients and for this we will need statistical grounds from systematic clinical trials.
One clinical study including 58 patients with advanced non-small cell lung cancer reported in 2020 that H2 therapy was able to relieve pulmonary symptoms compared to a control group that received no treatment. The hydrogen-group was administered H2 by inhalation for 4–5 h per day for 5 months. The same hydrogen-treatment was also given to non-small cell lung cancer patients in combination with either chemotherapy, targeted therapy or immunotherapy. After 16 months, the progression-free survival was higher for the hydrogen-only treatment group, and significantly higher for all the combination-treatment groups, as compared to the control group [25]. Another trial reported benefits of H2 treatment in 42 lung cancer patients treated with nivolumab. Significantly longer overall survival was found for the combination treatment with H2 gas compared to those treated with nivolumab only. It was suggested that the two therapeutic agents might exhibit synergistic effects as mitochondrial activators [26]. It is reasonable to treat lung cancer with H2 inhalation to target the disease site, even though systemic effects have been observed. Other cancer types that have shown positive outcomes from H2 therapy by inhalation or drinking include liver, nasopharyngeal and colorectal cancer [27,28,29] as well as head and neck cancer (see Table 1).
Interesting immune-modulating effects of H2 administration have been observed in cancer patients. A high proportion of immune cells of the type CD8+ T cells expressing the programmed cell death protein-1 (PD-1) is often seen in cancer patients and can be associated with poor cancer prognosis. PD-1 is an immune checkpoint receptor that guards against autoimmunity and is often involved in immunotherapy treatment (PD-1 inhibitors) as it makes the immune system “oversee” cancer cells. The administration of H2 has been shown to reduce the proportion of PD-1+ CD8+ T cells in the blood of cancer patients. This has been observed in both late-stage colorectal carcinoma and lung cancer patients in separate clinical trials and H2 has shown to improve cancer prognosis in both patient groups [26,29]. Furthermore, H2 can improve the efficacy of nivolumab treatment in cancer patients with high levels of PD-1+ CD8+ T cells, which previously had a poor response to nivolumab [26]. A significant decrease in the proportion of PD-1+ CD8+ T cells after H2 inhalation treatment was also seen in a case study of a gallbladder carcinoma patient [22]. The loss of immunological activity in the CD8+ T cells may be due to mitochondrial dysfunction, in which H2 is found to be an important player. The colorectal carcinoma patients treated with a combined therapy of H2 and nivolumab showed a significantly longer overall survival than the patients who were treated with nivolumab alone [30]. Another study found that patients with non-small cell lung cancer that inhaled H2:O2 (2:1) without other treatments resulted in reestablishment of normal levels of six cell subsets involved in our immune system, including cytotoxic T cells, T helper cells and natural killer cells [31]. From these appealing results, the use of H2 could be interesting in combination with immunotherapy for modulating immune reactions towards cancer cells.
In addition to the direct effects of H2 therapy in controlling tumor progression, several cell and animal studies [32,33,34,35] have shown that H2 can be effective in alleviating side-effects without reducing anti-tumor activity of standard cancer treatment. The array of side-effects may be experienced as devastating for the quality of life of cancer patients and survivors alike. Therefore, clinical studies have investigated the effect of H2 on chemo- and radiotherapy induced injuries. A study with 134 colorectal cancer patients found that hydrogen-rich water can alleviate mFOLFOX6 chemotherapy-induced liver injuries [36]. Non-small cell lung cancer patients undergoing chemotherapy, targeted therapy or immunotherapy treatment experienced a decrease in adverse events after H2 administration, and for some it even disappeared [25].
Radiotherapy is an important treatment for several cancer diseases. Side-effects of radiotherapy are often associated with increased generation of ROS that can potentially be reduced with H2 treatment. One study tested whether six weeks of drinking H2-rich water improved the quality of life for 49 patients with liver tumors who received radiotherapy. It was shown that H2-rich water consumption reduced the biological response to oxidative stress induced by radiation without comprising the anti-tumor effects of radiotherapy. Quality of life-scores were significantly improved for patients receiving H2-therapy in combination with radiotherapy compared to patients receiving placebo water [27]. An observational study found that H2 inhalation treatment can significantly alleviate radiotherapy-induced bone marrow damage, such as the reducing effects of white blood cells and platelets, without compromising the anti-tumor effects [37]. Adverse reactions like difficulty of swallowing, brain injury and hearing loss are often experienced after radiotherapy for nasopharyngeal cancer. Three nasopharyngeal cancer patients were reported to have moderate-extremely severe hearing loss and needed hearing aids after radiotherapy. The patients received H2 administered by inhalation for four hours every day (2:1 = H2:O2). After 1–2 months, the patient’s binaural hearing had improved considerably, and one of the patients no longer needed a hearing aid [28]. These findings are promising, however, more research is needed to reach definitive conclusions.
Molecules 28 07785 g003
Figure 3. Schematic overview of the effects of hydrogen therapy in cancer treatment. The top images show MR imaging of brain metastasis (arrow) before (left) and after (right) H2 treatment, adapted from [24]; OncoTargets and Therapy 2019:12 11145-11151—originally published by, adapted and used with permission from Dove Medical Press Ltd., Macclesfield, UK. The middle figures show alterations in cytotoxic and helper T cell levels in cancer patients after H2 treatment, adapted from [31]. The parallel red lines show the normal range of cell levels and the black short lines show the measured average values at each time point. The bottom left figure shows number of months (mon) with progression-free survival (PFS) of lung cancer patients receiving no treatment (control), H2 therapy (H2 only), or combined treatments with H2 and immunotherapy (immuno), targeted therapy (target) or chemotherapy (chemo). The black short lines show the average PFS values for each treatment. Adapted from [25]. The bottom right figure shows the quality of life (QOL) scores of patients treated with radiotherapy for liver tumors, with or without H2 water, adapted from [27]. A higher score reflects more symptoms and lower QOL. * p < 0.05, ** p < 0.01, *** p < 0.001, for all figures.
Figure 3. Schematic overview of the effects of hydrogen therapy in cancer treatment. The top images show MR imaging of brain metastasis (arrow) before (left) and after (right) H2 treatment, adapted from [24]; OncoTargets and Therapy 2019:12 11145-11151—originally published by, adapted and used with permission from Dove Medical Press Ltd., Macclesfield, UK. The middle figures show alterations in cytotoxic and helper T cell levels in cancer patients after H2 treatment, adapted from [31]. The parallel red lines show the normal range of cell levels and the black short lines show the measured average values at each time point. The bottom left figure shows number of months (mon) with progression-free survival (PFS) of lung cancer patients receiving no treatment (control), H2 therapy (H2 only), or combined treatments with H2 and immunotherapy (immuno), targeted therapy (target) or chemotherapy (chemo). The black short lines show the average PFS values for each treatment. Adapted from [25]. The bottom right figure shows the quality of life (QOL) scores of patients treated with radiotherapy for liver tumors, with or without H2 water, adapted from [27]. A higher score reflects more symptoms and lower QOL. * p < 0.05, ** p < 0.01, *** p < 0.001, for all figures.
Molecules 28 07785 g003

6.3. Respiratory Diseases

When listing the leading causes of death worldwide, respiratory conditions come third [14], and they are still in need of new pharmaceutical solutions. A gas mixture of helium and oxygen has been used for decades to treat obstructive pulmonary disease for its lower density, higher viscosity and reduced airway resistance compared to the conventional nitrogen-oxygen mixtures [38]. Using oxygen-hydrogen mixtures can have similar effects, in addition to the therapeutic antioxidant effects of H2.
In 2020, a study that examined the acute effects of inhalation of H2-containing gas found that inflammatory status in asthma and COPD patients was attenuated by the treatment. The trial included 20 asthma and COPD patients that inhaled a 2.4% H2-containing steam mixed gas for a single inhalation period of 45 min. This treatment significantly decreased inflammation markers like monocyte chemotactic protein 1, IL-4 and IL-6 levels in both COPD and asthma patients [39]. In 2021, a larger clinical trial was conducted with 108 patients with acute exacerbation of COPD receiving either H2:O2 or O2 therapy. They found superior improvement in symptoms in the H2:O2 group with significant results in certain test scores [40], showing that COPD is an interesting indication for H2 therapy. The authors have not been successful in identifying more extensive studies of hydrogen therapy for asthma, despite the positive findings. Another clinical study from 2018 evaluated the efficacy and safety of breathing H2 in acute severe tracheal stenosis patients. Thirty-five patients were administered H2:O2 gas mixture (2:1) for 15 min and 120 min (6 L/min) in two consecutive breathing steps. All the measured endpoint parameters except vital signs were improved after inhaling H2, including inspiratory effort as assessed by diaphragm electromyography (EMGdi), transdiaphragmatic pressure (Pdi), Borg score, and impulse oscillometry (IOS) [41]. These clinical studies show that H2 inhalation is a promising treatment option for respiratory diseases, which is a suitable administration method both for targeting the diseased tissue and for convenience as breathing devices are often used by respiratory disease patients. Additionally, the inhalation of H2 has also been tested in COVID-19 infected patients for treating respiratory symptoms, with very promising results (see Section 6.5).

6.4. Central Nervous System Diseases

Conditions affecting the central nervous system (CNS) represent one of the major public health challenges today. Dementia and other diseases causing cognitive decline are correlated with an aging population which is an increasing problem and new medications to treat these diseases are badly needed. Molecular hydrogen is the smallest molecule, and its very small size and nonpolar nature makes it highly diffusible. It can even pass through the blood-brain barrier which is a major obstacle for medical treatment of the brain [8].
A few clinical studies have investigated the effects of hydrogen therapy on acute damage to the brain caused by cardiac occurrences, all of them showing benefits of H2 administration. In one study, thirty-seven patients with poor-grade subarachnoid hemorrhage were given a H2-rich solution by infusion for 14 days together with intracisternal magnesium sulfate infusion, or only intracisternal magnesium sulfate infusion. Incidences of cerebral vasospasm and delayed cerebral ischemia were significantly lower in the treatment groups and H2-therapy had additional effects by decreasing serum malondialdehyde, a marker of oxidative stress, reduced biomarkers for neuronal damage and physical therapy improvement by the Barthel Index [42]. In another study, 25 patients with cerebral infarction were given H2 inhalation (3% H2 gas) treatment for one hour twice a day. H2 inhalation, compared to control, gave significant effects on lower relative MRI signal, indicating less severe infarction site, neurological improvement seen by NIHSS scores and improved Barthel Index scores [43]. Improved MRI indices for brainstem infarction patients were also observed after intravenous administration of H2-rich saline, in combination with edaravone. The results were better for the combined treatment than for edaravone treatment alone [44]. For giving direct access to the brain via the blood-brain barrier, H2-rich saline is more often administered intravenously in clinical trials involving brain disorders as compared to drinking and inhalation that is more widely used for other conditions. This can also be due to convenience because critically ill patients are hospitalized and are typically prepared for IV administration of various drugs. However, other administration routes might also be useful for treating critically ill patients. A large-scale trial with 73 patients at 15 hospitals in Japan studied the effect of H2 inhalation on neurological outcomes for patients with brain ischemia during post-cardiac arrest. The patients were randomly assigned to receive O2 with or without 2% H2 for 18 h. An increase was seen in the primary neurological outcome, however, this was not statistically significant. The reported statistical significance in the secondary outcomes, on the other hand, including an increase in 90-day survival, suggests that H2 inhalation may have therapeutic benefits without neurological deficits [45].
Clinical trials with hydrogen therapy have also been conducted with patients with cognitive disorders including Alzheimer’s and Parkinson’s disease, as reduced neurodegeneration have been seen from several animal studies with H2 [46,47,48]. In one human study, 73 patients with mild cognitive impairment drank 300 mL of H2-enriched water or placebo water every day for a year and their Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) scores were then determined. The study found that carriers of the apolipoprotein E4 (APOE4) genotype significantly improved their total ADAS-cog scores after drinking H2 water when compared to the control group. This indicates that genetic variations can affect how subjects respond to hydrogen treatment. However, there was no significant difference between the H2 and the control groups in ADAS-cog scores after 1 year [49]. Another study involving eight patients diagnosed with Alzheimer’s disease suggests that 3% H2 inhalation can relieve symptoms and has disease-modifying effects. Improvements in ADAS-cog scores and integrity of neurons, seen by diffusion tensor imaging (DTI), were significant during the 6-month follow-up but non-significant after one year, compared to untreated patients [50].
A trial tested H2 inhalation in 20 Parkinson’s disease patients. The inhalation of either low dose H2 of ~1.3% in air or placebo for 10 min twice a day for 4 weeks did not result in any beneficial effects. However, another interesting finding of increased 8-hydroxy-2′-deoxyguanosine (8-OHdG, an indicator of cellular oxidative stress) and other reported stress responses, suggest that beneficial effects of hydrogen therapy are partly or largely mediated by hormetic mechanisms [51]. A larger-scale similar study following 178 patients over 72 weeks revealed no disease improvement by oral H2 consumption (1 L/day) in patients with Parkinson’s disease [52]. Even though beneficial effects of hydrogen therapy were not found in this large-scale study of Parkinson’s disease, combinatory treatment might show more benefits. A pilot study including 18 patients with Parkinson’s disease found significant improvements in the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores compared with the baseline after combined treatment of daily drinking H2-saturated water and photobiomodulation (PBM) over a two-week period. The report attributes the positive effects to “PBM targeting the brainstem may facilitate neuronal activity, and the concomitant H2 may clear additional ROS produced by PBM” [53]. A randomized, double-blind pilot study performed in 2013 including 18 Parkinson’s disease patients treated with levodopa showed that drinking 1 L of H2 water every day for 48 weeks significantly improved the UPDRS scores [54]. The improvements can, however, be attributed to the alleviation of side-effects of the other drug taken in combination, as observed for cancer treatments.

6.5. Infections

A flourishment of H2 therapy occurred as the pandemic of the Coronavirus disease 2019 (COVID-19) spread globally. H2 inhalation has been used to treat respiratory-related COVID-19 symptoms in several clinical studies, primarily for the same reasons as its use in other respiratory conditions, namely a reduction in gas density and airflow resistance. However, the studies do not rule out possible beneficial antioxidant effects of H2.
A pioneering clinical study conducted with 100 patients at seven different Chinese hospitals found exclusively positive results of continuous inhalation of H2:O2 2:1 gas mixture (3 L/min) in all the end-point parameters, compared to standard oxygen treatment, as shown in Figure 4. The primary endpoint was disease severity, and the secondary endpoints were dyspnea, cough, chest distress, chest pain and oxygen saturation, and all were significantly improved after just two days of treatment compared to control [55]. These excellent outcomes resulted in the inclusion of this specific treatment (H2:O2 inhalation 2:1) as a recommendation by the China National Health Commission in the “Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition)” [56], next to standard oxygen therapy. This practice does not seem to have attracted attention globally in the combat against COVID-19, and additional clinical trials have been performed (see Table 1). A study published in 2022 investigated the use of H2 therapy in rehabilitation of 50 acute post-COVID-19 patients. They found significant improvements in 6-min walking test distance, forced vital capacity and expiratory volume when administered H2 by inhalation. The protocol described at-home inhalation of 100% H2 at low flow rate (250 mL/min) for 60 min twice a day for two weeks [57].
A retrospective study, also published in 2022, of medical records of twelve COVID-19 patients that were subject to H2:O2 therapy by inhalation found suppression of inflammatory responses, compared to standard treatment. For the H2 group, the results showed a significant decrease in neutrophil percentage and the concentration of C-reactive protein [58]. In summary, H2 inhalation can be beneficial for COVID-19 patients for at least three different reasons; (i) a reduction of ROS levels, (ii) reduced airflow resistance for eased respiratory conditions and (iii) a reduction in inflammatory responses. All the positive results of both improved physical and respiratory function in COVID-19 patients have demonstrated the clinical usability of this novel therapeutic strategy.
Hydrogen therapy in the treatment of other infections has shown health-promoting effects in various animal models including sepsis and periodontitis, a serious gum infection, by reducing inflammation and sepsis-induced injuries [59,60,61]. No in-human studies have investigated the effect of H2 on sepsis, but one clinical study found elevated oxidative stress levels in patients with chronic hepatitis B. Sixty patients were included, some were administered 1.2–1.8 L/day of H2-rich water, and some were given routine treatment for 6 consecutive weeks. A significant reduction in ROS was seen after H2 therapy, compared to the control group. Improved liver function and hepatitis B DNA levels were comparable after both H2 and control treatment, and the report suggests that longer-term studies might be needed to confirm the physiological effects of H2 on the reduction of oxidative stress [62]. To summarize, the treatment of infection-related symptoms using H2 has shown positive outcomes, but there has been no documentation that the underlying infection itself is affected by H2 therapy.

6.6. Lifestyle-Related Conditions and Exercise

Hydrogen therapy has also been used in the treatment of lifestyle-related and metabolic conditions, which is an increasing problem with an increasingly heavier population. Many studies also point to the beneficial effects of H2 therapy in relation to exercise and sports-related injuries, including administration forms like H2 inhalation, drinking of H2-rich water and topical H2 application. A pilot study found that oral intake of H2-rich water prevented an elevation of blood lactate and decreased muscle fatigue during heavy exercise in ten male elite soccer players and suggests that it can be a suitable means of hydration for athletes [63]. Another study involving eight male cyclists found similar results, oral intake of H2-saturated water improved performance in intermittent cycling exercises when the duration was longer than 30 min (anaerobic) [64]. A clinical trial involving ten men and ten women found an increase in peak running velocity up to 4.2% in a running time-to-exhaustion test after seven days of inhaling 4% H2 for 20 min each day [65]. One study showed that drinking H2-rich water before and after strenuous exercise reduced the exercise-induced increase in ROS levels in eight male volunteers. This might help prevent accumulative muscular fatigue even though exercise performances were not significantly different over the two 3-day consecutive exercise tests, compared to placebo water [66]. A larger-scale study investigated the effects of drinking H2-enriched water right before cycle ergometer exercise sessions in healthy non-trained (n = 99) and trained (n = 60) participants. They found that H2-water, compared to placebo water, enhanced endurance and relieved psychometric fatigue as measured by maximal oxygen consumption and Borg’s scale and visual analogue scales, respectively [67]. Additionally, healing of acute sports-related soft tissue injuries can be positively impacted by both oral and topical H2 treatment for 2 weeks, next to standard-care [68]. Flipping the coin from high-level exercise, H2 therapy has also been studied for managing lifestyle-related disease states. Typically drinking 1–2 L of H2-rich water daily is shown to reduce ROS levels and contribute to body fat reduction in overweight people [69], as well as managing lipid and glucose metabolism in patients with diabetes type 2 [70] and metabolic syndrome [71,72,73,74].

6.7. Other Diseases and Conditions

Outside the major disease areas discussed herein, several clinical studies investigating H2 on other indications related to high oxidative stress levels have been reported. Rheumatoid arthritis is an autoimmune disease characterized by chronic inflammation and the destruction of bone and cartilage. Elevated hydroxyl radical levels are thought to be involved in pathogenesis, for which H2 therapy can have a selective scavenging effect. Both drinking and injection of H2-enriched water and saline have been tested for the treatment of rheumatoid arthritis in separate clinical trials. In one study, twenty patients drank 530 mL of H2-rich water/day for 4 weeks in two separate periods. In another study, 24 patients were randomly assigned either H2-saline or placebo-saline which was administered intravenously by drop infusion of 500 mL daily for 5 days. The results of both studies showed that H2 significantly reduced biomarkers for oxidative stress (for instance urinary 8-hydroxydeoxyguanine) and disease activity score in 28 joints (DAS28), by C-reactive protein levels. This was accompanied by significant improvements in rheumatoid arthritis symptoms [75,76]. Chronic graft-versus-host-disease can also be considered an autoimmune disease. A longer-term study over 12 months found therapeutic effects of daily drinking H2-rich water at a dose of 12 mL/kg. Out of the 24 patients enrolled, 18 had an objective response as measured in seven domains (skin, mouth, gastrointestinal, liver, eyes, lungs and joints and fascia) using the National Institutes of Health (NIH) Consensus form for measuring therapy response for chronic graft-versus-host-disease. The survival time and the survival rate at 4 years was significantly prolonged in the response group, compared to the nonresponse group. There is currently no standard therapy for chronic graft-versus-host-disease patients refractory or dependent to corticosteroid treatment, and therefore H2 can serve as a good option [77].
Another worldwide health issue, without any approved medications, is non-alcoholic fatty liver disease (NAFLD), causing hepatic dysfunction. Metabolic impairment plays a major role in NAFLD pathogenesis, so pharmaceuticals that advance lipid and glucose metabolism are of interest for treating this disease. Hydrogen possibly has these properties, as seen from the results of the clinical trials with diabetes and metabolic syndrome patients. NAFLD can also be associated with inflammation, excess oxidative stress and aberrant cellular signaling. Two separate clinical trials studied the effect of oral intake of H2-rich water at 1 L/day. One of them included 12 subjects and found that after one month, the H2 therapy significantly reduced liver fat accumulation, as compared to placebo, with no significant differences in body weight and composition [78]. The second study involved 30 subjects and lasted for 2 months and found non-significant decreases in levels of NAFLD disease markers, as well as weight and body mass index. Interestingly, non-significant increase tendencies of oxidative stress markers (8-hydroxy-2′-deoxyguanosine and malondialdehyde) were also found, which was explained by the hormetic effects of H2 occurring prior to the significant clinical improvements over the longer-term [79]. Another study tested 13-week inhalation of H2:O2 (2:1) gas mixture at rate of 3 L/min for 1 h/day in 43 NAFLD patients with moderate-severe cases. Improvements in serum lipid and liver enzymes and significantly improved liver fat content was found. Additional studies in mice models revealed that this effect of H2 was possibly caused by promoting hepatic autophagy [80].
Some specific conditions have been studied for the effect of H2-enrichment in other administration forms such as solutions for dialysis and via the eyes. One study demonstrated significant effects of using H2 solutions during cataract surgery (phacoemulsification) to restore vision. The procedure employs ultrasound which produces free radicals that can potentially be neutralized with H2-enriched solutions. Thirty-two patients with cataracts in both eyes were treated with the conventional method on one eye and using H2-enriched solution on the other eye. Reduction rates of endothelial cell density, the primary endpoint, were significantly smaller in the H2 group at all the measured time points [81].
Hemodialysis patients experiencing chronic inflammation have poor prognoses and therapeutic approaches are limited. Therefore, the anti-inflammatory properties of H2 can be utilized in the dialysis solution for these patients. Two studies performed by the same research group, published in 2010 and 2018, investigated the effects of H2-infused dialysate, with H2 from water electrolysis, in the treatment of hemodialysis patients. In the 2010 study, 21 patients were switched to H2-enriched dialysis solution for 6 months, resulting in significant decreases in systolic blood pressure compared to before the test period. A significant decrease in plasma inflammation markers were also identified [82]. The 2018 study was longer-term and had a larger test group of 161 and 148 patients administered H2-enriched and conventional dialysis solutions, respectively, over a 3.3-year observation period. Reductions in post-dialysis hypertension were found and multivariate analysis revealed H2-enriched dialysis as an independent significant factor for the primary endpoint, which was a composite of all-cause mortality and development of non-lethal cardio-cerebrovascular events [83]. In both studies, H2 caused minimal changes in dialysis parameters but the positive results including improved blood pressure control and ameliorated inflammatory reactions could improve the prognosis of chronic hemodialysis patients.
Others have studied H2 therapy for the treatment of various diseases involving inflammation and pain. Four patients with acute erythematous skin diseases with fever and/or pain experienced significant improvement in symptoms, that did not recur, after infusion with H2-enriched fluid (500 mL/day for 3 days) [84]. Twenty-eight patients with interstitial cystitis/painful bladder syndrome were given H2-rich water or placebo water for 8 weeks. Even though H2-rich water was extremely effective in improving the bladder pain score in 11% of the patients, the improvements were not significantly different from that of placebo [85]. H2-enriched water has also been tested on patients with mitochondrial and inflammatory myopathies. Observations included improved mitochondrial dysfunction in mitochondrial myopathy patients and inflammatory processes in patients with polymyositis/dermatomyositis. Significant improvements in certain disease markers were observed, even though the improvement in clinical symptoms was not significant. Two different therapy schemes were followed, where 14 patients drank 1 L/day for 12 weeks and 22 patients drank 0.5 L/day for 8 weeks. Less prominent effects were seen for the lower amount scheme, illustrating a dose-dependent response of H2 therapy [86].

7. Summary and Discussion

Qualitative and quantitative analysis of the current data related to human use of H2 therapy has been conducted herein, encompassing over 64 clinical studies and 81 registered clinical trials. All the studies have unequivocally confirmed the safety and legitimacy of H2 in human consumption in all the administration methods tested, and therefore set the foundation for clinical trials for a variety of indications. The high numbers of ongoing clinical trials registered over the recent years underscores the global effort for rapid introduction of H2 therapy in various disease areas spanning chronic to acute stages. Phase 2 and 3 clinical trials are ongoing, yet the area is still in its infancy.
The exploration of H2 consumption’s efficacy has encompassed several interesting indications spanning the major disease areas. Noteworthy positive outcomes have emerged among patients suffering from myocardial infarction, an array of cancers (lungs, liver, colorectal and gallbladder), asthma, COPD, brain ischemia, COVID-19, rheumatoid arthritis, non-alcoholic fatty liver disease and in hemodialysis patients. Also, lifestyle-related indications have shown promising results, including type 2 diabetes, obesity and exercise performance. Given the molecular effects of mitigating the most damaging reactive oxygen species, H2 should be most effective in treating diseases correlated with high levels of oxidative stress. Moreover, most disease states involve dysregulation of ROS and therefore it can be a diverse medication. Promisingly, several clinical studies have identified the reduction of oxidative stress biomarkers, confirming the mechanism of action. Despite these robust indicators, the road to clinical translation might prove more intricate compared to conventional new drugs that are developed by pharmaceutical companies and tailored to specific indications.
Respiratory health emerges as a promising arena for hydrogen therapy, particularly in the context of respiratory diseases and COVID-19 infections. This is evidenced by the integration of H2 inhalation in the China National Health Commission’s recommendation for COVID-19 treatment. While the reduction in airway resistance due to the low density of H2 is a possible factor, its antioxidant potential can have additional benefits.
Cancer remains an interesting field for H2 therapy, offering not only direct effects on cancer progression but also demonstrating relief from side-effects of standard treatments. Furthermore, synergistic effects from combining H2 with conventional treatments, such as chemotherapy and radiotherapy, hold promise for optimizing therapeutic outcomes and enhancing overall quality of life. The observed immuno-modulating effects of H2 have the potential to complement immunotherapy, which further augments its therapeutic potential. Hydrogen therapy has been used to complement conventional therapies in clinical trials including cardiac arrest, brainstem infarction and Parkinson’s disease patients, in addition to cancer. Due to low side-effects and potential beneficial effects, the health risks can be greater for not using H2 in combination with standard treatments across a broad spectrum of conditions from cancer to sports-related injuries.
Ideally, H2 therapy would be beneficial for diseases that currently have no treatment options. Cognitive disorders, which are increasing concurrently with the elderly population, exemplify such unmet needs. While small-scale human trials offered hope for therapeutic effects of H2 in Parkinson’s and Alzheimer’s disease, large-scale studies have found no significant positive results. Use in other diseases without standard medical regimes, however, such as non-alcoholic fatty liver disease or hemodialysis, shows promise. In summation, the landscape of H2 therapy’s clinical utility is multifaceted and promises both challenges and opportunities, yet its integration with conventional treatments warrants further exploration.
Undeniably, the administration method plays a major role in disease treatment. Oral consumption of H2-rich water, suitable for most diseases, and inhalation of H2 gas mixtures, used prominently for respiratory symptoms, are emerging as the predominant methods. Low-dose (4% or below) H2 inhalation is often used to mitigate the explosion risk. Injection is most relevant for hospitalized patients and the use of H2-enriched dialysis solutions and water baths show potential in suitable disease contexts. Another factor in the therapeutic equation is the dose of H2 administered. Inhalation enables sustained, safe high-dose administration, while drinking may necessitate consumption of either large amounts of saturated water or high concentration of supersaturated water in order to obtain an optimal H2 dose.
Innovations within micro- and nanomaterial drugs for in vivo H2 generation are promising for advancements of the field [87,88]. These new drugs can allow for feasible oral administration of a tablet that will dissolve in the gastrointestinal (GI) system and, in reaction with the water available, produce H2 that can freely diffuse throughout the body. Some candidate materials include magnesium (Mg), magnesium hydride (MgH2) and silicon (Si) that can react with water to produce H2 in the following reactions:
Mg + 2H2O → Mg(OH)2 + H2
MgH2 + 2H2O → Mg(OH)2 + 2H2
Si + 2H2O → SiO2 + 2H2
Reaction (1) follows the same principle as the Mg effervescent tablets for H2-rich water generation. The theoretical capacity (at SATP: 1 bar and 25 °C) is 1.02 L/g and animal studies have shown that Mg-containing materials can produce H2 for treatment of osteoarthritis and gastric cancer [89,90,91]. MgH2 can produce more H2, up to 1.89 L/g, and oral MgH2 administration to mice has been shown to alter gene expression to enhance fatty acid metabolism [92]. The use of MgH2 in vase water is also shown to be applicable in postharvest flower preservation by extending the vase life of cut roses [93]. Si has a theoretical H2 generation capacity of 1.77 L/g (reaction 3) and Si nanoparticles have been shown as an effective candidate for H2 generation in simulated GI environments [94]. Animal studies have confirmed positive effects of orally administered H2-generating Si in several disease models including pneumonitis, ischemia-reperfusion injury and Parkinson’s disease [95,96,97]. Other materials have also been studied, including H2-producing coral calcium hydride that has been shown to reverse brain damage and alleviate oxidative stress and neuroinflammation induced by methamphetamine exposure in mice [98]. The realization of these types of technologies could enable feasible at-home administration of high doses of H2. For instance, from a 65 mg Si tablet, more than 100 mL of H2 can be generated inside the body, which is equivalent to drinking more than 5 L of H2-saturated water.
Hydrogen precursors, for instance Mg or Si particles, can be regarded as hydrogen prodrugs and will, as new chemical entities in drug products, require preclinical and clinical documentation including safety of the materials and the by-products. The in vivo kinetics of H2 generation after ingestion will also have to be documented and potentially optimized. Nevertheless, hydrogen therapy holds the potential to emerge as the next breakthrough in the clinical application of nanomedicine. Despite this promise, clinical trials utilizing this cutting-edge technology are yet to be conducted.
The realization of H2 therapy’s full potential faces nuanced challenges. Unlike conventional drugs, the medical use of H2 cannot directly be protected by intellectual property rights. This might dampen pharmaceutical industry support for clinical trials. However, patenting technology for H2 production devices, such as inhalation devices, and new delivery systems is possible. Therefore, the development of these technologies might be necessary for realizing the clinical potential of H2 therapy.

8. Conclusions

In summary, we are confident that H2 therapy will gain recognition as a viable therapeutic treatment approach in the future, for some specific diseases and conditions. However, several of the performed clinical studies might be regarded as anecdotal clinical studies, and future recommended clinical use of hydrogen for treatment of a specific indication might require comparative, double blinded, randomized clinical studies according to guidelines for clinical documentation of new drug substances. Future recommended clinical use of hydrogen requires medical quality of hydrogen gas. Additionally, the medical use of hydrogen requires safe, efficient and practical ways for administration to the patient which might be realized with technological innovations, for instance within nanomedicine.

Author Contributions

Conceptualization, J.K.; methodology, H.M.J., M.H. and J.K.; formal analysis, H.M.J.; investigation, H.M.J. and J.K.; writing—original draft preparation, H.M.J.; writing—review and editing, M.H. and J.K.; visualization, H.M.J.; supervision, M.H. and J.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Research Council of Norway under the NANO2021 program, project number 313954.

Data Availability Statement

Data will be made available on request.

Conflicts of Interest

Jo Klaveness and Hennie Marie Johnsen are inventors of a patent application with the title “Silicon particles for hydrogen release”. The assignee of the patent application is Nacamed AS. Jo Klaveness is a consultant for and has shares in Nacamed AS.

References

  1. Zhang, J.H.; Matei, N.; Camara, R. Emerging mechanisms and novel applications of hydrogen gas therapy. Med. Gas Res. 2018, 8, 98–102. [Google Scholar] [CrossRef] [PubMed]
  2. Sun, Q.; Han, W.; Nakao, A. Biological safety of hydrogen. In Hydrogen Molecular Biology and Medicine; Springer: Dordrecht, The Netherlands, 2015; pp. 35–48. [Google Scholar] [CrossRef]
  3. Ohsawa, I.; Ishikawa, M.; Takahashi, K.; Watanabe, M.; Nishimaki, K.; Yamagata, K.; Katsura, K.-I.; Katayama, Y.; Asoh, S.; Ohta, S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 2007, 13, 688–694. [Google Scholar] [CrossRef] [PubMed]
  4. Venable, C.S.; Fuwa, T. The solubility of gases in rubber and rubber stock and effect of solubility on penetrability. Ind. Eng. Chem. 1922, 14, 139–142. [Google Scholar] [CrossRef]
  5. Mehio, N.; Dai, S.; Jiang, D.-E. Quantum Mechanical Basis for Kinetic Diameters of Small Gaseous Molecules. J. Phys. Chem. A 2014, 118, 1150–1154. [Google Scholar] [CrossRef] [PubMed]
  6. Haynes, W.M. (Ed.) CRC Handbook of Chemistry and Physics, 95th ed.; CRC Press LLC: Boca Raton, FL, USA, 2014; pp. 4–66. [Google Scholar]
  7. Liu, C.; Kurokawa, R.; Fujino, M.; Hirano, S.; Sato, B.; Li, X.-K. Estimation of the hydrogen concentration in rat tissue using an airtight tube following the administration of hydrogen via various routes. Sci. Rep. 2014, 4, 5485. [Google Scholar] [CrossRef] [PubMed]
  8. Sano, M.; Ichihara, G.; Katsumata, Y.; Hiraide, T.; Hirai, A.; Momoi, M.; Tamura, T.; Ohata, S.; Kobayashi, E. Pharmacokinetics of a single inhalation of hydrogen gas in pigs. PLoS ONE 2020, 15, e0234626. [Google Scholar] [CrossRef] [PubMed]
  9. Grandviewresearch.com. Hydrogen Generation Market Size, Share & Trends Analysis Report by System (Merchant, Captive), by Technology (Steam Methane Reforming, Coal Gasification), by Application, by Source, by Region, and Segment Forecasts, 2023–2030. Available online: https://www.grandviewresearch.com/industry-analysis/hydrogen-generation-market (accessed on 30 September 2023).
  10. Ostojic, S.M. Molecular hydrogen: An inert gas turns clinically effective. Ann Med. 2015, 47, 301–304. [Google Scholar] [CrossRef]
  11. Rostain, J.C.; Gardette-Chauffour, M.C.; Lemaire, C.; Naquet, R. Effects of a H2-He-O2 mixture on the HPNS up to 450 msw. Undersea Biomed. Res. 1988, 15, 257–270. [Google Scholar]
  12. Abraini, J.H.; Gardette-Chauffour, M.C.; Martinez, E.; Rostain, J.C.; Lemaire, C.; Dalecki, M.; Bock, O.; Schulze, B.; Dean, J.B.; Mulkey, D.K.; et al. Psychophysiological reactions in humans during an open sea dive to 500 m with a hydrogen-helium-oxygen mixture. J. Appl. Physiol. 1994, 76, 1113–1118. [Google Scholar] [CrossRef]
  13. Ono, H.; Nishijima, Y.; Adachi, N.; Sakamoto, M.; Kudo, Y.; Kaneko, K.; Nakao, A.; Imaoka, T. A basic study on molecular hydrogen (H2) inhalation in acute cerebral ischemia patients for safety check with physiological parameters and measurement of blood H2 level. Med. Gas. Res. 2012, 2, 21. [Google Scholar] [CrossRef]
  14. Roser, M. 07.12.21. Causes of Death Globally: What Do People Die From? Published Online at OurWorldInData.org. Available online: https://ourworldindata.org/causes-of-death-treemap (accessed on 30 September 2023).
  15. Zanini, D.; Todorovic, N.; Korovljev, D.; Stajer, V.; Ostojic, J.; Purac, J.; Kojic, D.; Vukasinovic, E.; Djordjievski, S.; Sopic, M.; et al. The effects of 6-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in older adults aged 70 years and over: A randomized controlled pilot trial. Exp. Gerontol. 2021, 155, 111574. [Google Scholar] [CrossRef]
  16. HoHo Biotech, 28.03.21. The Hydrogen Production Factory of the Body, Hydrogen Coral Hydrogen Capsules (Produced by GMP Factory in Japan). Available online: https://www.hoholab.com.tw/post/%E8%BA%AB%E9%AB%94%E7%9A%84%E7%94%A2%E6%B0%AB%E5%B7%A5%E5%BB%A0%EF%BC%8C%E6%B0%B4%E7%B4%A0%E7%8F%8A%E7%91%9A%E6%B0%AB%E8%86%A0%E5%9B%8A (accessed on 16 August 2023).
  17. Shen, M.C.; Chung, J.R.C.; Wang, K.Y.; Chu, C.F.; Tsou, W.H.; Chou, H.Y.; Wang, T.Y.; Chang, T.H.; Chen, W.W.; Liu, F.C.; et al. Evaluation of the Safety and Potential Therapeutic Effects of Hydrogen-Rich Coral Calcium on Autoimmune Diseases. Res. Sq. 2022; Preprint. [Google Scholar] [CrossRef]
  18. Tamura, T.; Hayashida, K.; Sano, M.; Suzuki, M.; Shibusawa, T.; Yoshizawa, J.; Kobayashi, Y.; Suzuki, T.; Ohta, S.; Morisaki, H.; et al. Feasibility and Safety of Hydrogen Gas Inhalation for Post-Cardiac Arrest Syndrome—First-in-Human Pilot Study. Circ. J. 2016, 80, 1870–1873. [Google Scholar] [CrossRef]
  19. Tamura, T.; Suzuki, M.; Hayashida, K.; Kobayashi, Y.; Yoshizawa, J.; Shibusawa, T.; Sano, M.; Hori, S.; Sasaki, J. Hydrogen gas inhalation alleviates oxidative stress in patients with post-cardiac arrest syndrome. J. Clin. Biochem. Nutr. 2020, 67, 214–221. [Google Scholar] [CrossRef]
  20. Katsumata, Y.; Sano, F.; Abe, T.; Tamura, T.; Fujisawa, T.; Shiraishi, Y.; Kohsaka, S.; Ueda, I.; Homma, K.; Suzuki, M.; et al. The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction—First Pilot Study in Humans. Circ. J. 2017, 81, 940–947. [Google Scholar] [CrossRef]
  21. Ishibashi, T.; Sakai, T.; Sato, B.; Hara, K.; Hara, Y.; Naritomi, Y.; Koyanagi, S.; Hara, H.; Nagao, T. Consumption of water containing over 3.5 mg of dissolved hydrogen could improve vascular endothelial function. Vasc. Health Risk Manag. 2014, 10, 591–597. [Google Scholar] [CrossRef]
  22. Chen, J.; Mu, F.; Lu, T.; Ma, Y.; Du, D.; Xu, K. A Gallbladder Carcinoma Patient With Pseudo-Progressive Remission After Hydrogen Inhalation. Onco Targets Ther. 2019, 12, 8645–8651. [Google Scholar] [CrossRef] [PubMed]
  23. Chen, J.-B.; Pan, Z.-B.; Du, D.-M.; Qian, W.; Ma, Y.-Y.; Mu, F.; Xu, K.-C. Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report. World J. Clin. Cases 2019, 7, 2065–2074. [Google Scholar] [CrossRef] [PubMed]
  24. Chen, J.; Mu, F.; Lu, T.; Du, D.; Xu, K. Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report. Onco Targets Ther. 2019, 12, 11145–11151. [Google Scholar] [CrossRef] [PubMed]
  25. Xu, K.-C.; Chen, J.-B.; Kong, X.-F.; Mu, F.; Lu, T.-Y.; Lu, Y.-Y. Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer. Med. Gas Res. 2020, 10, 75–80. [Google Scholar] [CrossRef] [PubMed]
  26. Akagi, J.; Baba, H. Hydrogen gas activates coenzyme Q10 to restore exhausted CD8+ T cells, especially PD-1+Tim3+terminal CD8+ T cells, leading to better nivolumab outcomes in patients with lung cancer. Oncol. Lett. 2020, 20, 258. [Google Scholar] [CrossRef]
  27. Kang, K.-M.; Kang, Y.-N.; Choi, I.-B.; Gu, Y.; Kawamura, T.; Toyoda, Y.; Nakao, A. Effects of drinking hydrogen-rich water on the quality of life of patients treated with radiotherapy for liver tumors. Med. Gas Res. 2011, 1, 11. [Google Scholar] [CrossRef] [PubMed]
  28. Chen, J.; Kong, X.; Mu, F.; Lu, T.; Du, D.; Xu, K. Hydrogen–oxygen therapy can alleviate radiotherapy-induced hearing loss in patients with nasopharyngeal cancer. Ann. Palliat. Med. 2019, 8, 746–751. [Google Scholar] [CrossRef] [PubMed]
  29. Akagi, J.; Baba, H. Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. Oncol. Rep. 2019, 41, 301–311. [Google Scholar] [CrossRef]
  30. Akagi, J. Immunological Effect of Hydrogen Gas-Hydrogen Gas Improves Clinical Outcomes of Cancer Patients. Gan Kagaku Ryoho 2018, 45, 1475–1478. [Google Scholar]
  31. Xu, K.-C.; Chen, J.-B.; Kong, X.-F.; Qian, W.; Mu, F.; Lu, T.-Y.; Lu, Y.-Y. Two weeks of hydrogen inhalation can significantly reverse adaptive and innate immune system senescence patients with advanced non-small cell lung cancer: A self-controlled study. Med. Gas Res. 2020, 10, 149–154. [Google Scholar] [CrossRef]
  32. Nakashima-Kamimura, N.; Mori, T.; Ohsawa, I.; Asoh, S.; Ohta, S. Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice. Cancer Chemother. Pharmacol. 2009, 64, 753–761. [Google Scholar] [CrossRef] [PubMed]
  33. Kikkawa, Y.S.; Nakagawa, T.; Taniguchi, M.; Ito, J. Hydrogen protects auditory hair cells from cisplatin-induced free radicals. Neurosci. Lett. 2014, 579, 125–129. [Google Scholar] [CrossRef]
  34. Chen, Y.; Zong, C.; Jia, J.; Liu, Y.; Zhang, Z.; Cai, B.; Tian, L. A study on the protective effect of molecular hydrogen on osteoradionecrosis of the jaw in rats. Int. J. Oral Maxillofac. Surg. 2020, 49, 1648–1654. [Google Scholar] [CrossRef]
  35. Mei, K.; Zhao, S.; Qian, L.; Li, B.; Ni, J.; Cai, J. Hydrogen protects rats from dermatitis caused by local radiation. J. Dermatol. Treat. 2014, 25, 182–188. [Google Scholar] [CrossRef]
  36. Yang, Q.; Ji, G.; Pan, R.; Zhao, Y.; Yan, P. Protective effect of hydrogen-rich water on liver function of colorectal cancer patients treated with mFOLFOX6 chemotherapy. Mol. Clin. Oncol. 2017, 7, 891–896. [Google Scholar] [CrossRef]
  37. Takefuji, Y.; Hirano, S.-I.; Aoki, Y.; Li, X.-K.; Ichimaru, N.; Takahara, S. Protective effects of hydrogen gas inhalation on radiation-induced bone marrow damage in cancer patients: A retrospective observational study. Med. Gas Res. 2021, 11, 104–109. [Google Scholar] [CrossRef]
  38. Morgan, S.E.; Vukin, K.; Mosakowski, S.; Solano, P.; Stanton, L.; Lester, L.; Lavani, R.; Hall, J.B.; Tung, A. Use of Heliox Delivered via High-Flow Nasal Cannula to Treat an Infant With Coronavirus-Related Respiratory Infection and Severe Acute Air-Flow Obstruction. Respir. Care 2014, 59, e166–e170. [Google Scholar] [CrossRef] [PubMed]
  39. Wang, S.T.; Bao, C.; He, Y.; Tian, X.; Yang, Y.; Zhang, T.; Xu, K.F. Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients. QJM Int. J. Med. 2020, 113, 870–875. [Google Scholar] [CrossRef] [PubMed]
  40. Zheng, Z.-G.; Sun, W.-Z.; Hu, J.-Y.; Jie, Z.-J.; Xu, J.-F.; Cao, J.; Song, Y.-L.; Wang, C.-H.; Wang, J.; Zhao, H.; et al. Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: Results of a multicenter, randomized, double-blind, parallel-group controlled trial. Respir. Res. 2021, 22, 149. [Google Scholar] [CrossRef] [PubMed]
  41. Zhou, Z.-Q.; Zhong, C.-H.; Su, Z.-Q.; Li, X.-Y.; Chen, Y.; Chen, X.-B.; Tang, C.-L.; Zhou, L.-Q.; Li, S.-Y. Breathing Hydrogen-Oxygen Mixture Decreases Inspiratory Effort in Patients with Tracheal Stenosis. Respiration 2019, 97, 42–51. [Google Scholar] [CrossRef] [PubMed]
  42. Takeuchi, S.; Kumagai, K.; Toyooka, T.; Otani, N.; Wada, K.; Mori, K. Intravenous Hydrogen Therapy With Intracisternal Magnesium Sulfate Infusion in Severe Aneurysmal Subarachnoid Hemorrhage. Stroke 2021, 52, 20–27. [Google Scholar] [CrossRef] [PubMed]
  43. Ono, H.; Nishijima, Y.; Ohta, S.; Sakamoto, M.; Kinone, K.; Horikosi, T.; Tamaki, M.; Takeshita, H.; Futatuki, T.; Ohishi, W.; et al. Hydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and Neuroprotection. J. Stroke Cerebrovasc. Dis. 2017, 26, 2587–2594. [Google Scholar] [CrossRef]
  44. Ono, H.; Nishijima, Y.; Adachi, N.; Tachibana, S.; Chitoku, S.; Mukaihara, S.; Sakamoto, M.; Kudo, Y.; Nakazawa, J.; Kaneko, K.; et al. Improved brain MRI indices in the acute brain stem infarct sites treated with hydroxyl radical scavengers, Edaravone and hydrogen, as compared to Edaravone alone. A non-controlled study. Med. Gas Res. 2011, 1, 12. [Google Scholar] [CrossRef]
  45. Tamura, T.; Suzuki, M.; Homma, K.; Sano, M.; Iizuka, R.; Narimiya, H.; Tsuruta, R.; Kaneda, K.; Fujita, M.; Sasaki, J.; et al. Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): A multi-centre, randomised, double-blind, placebo-controlled trial. EClinicalMedicine 2023, 58, 101907. [Google Scholar] [CrossRef]
  46. Fu, Y.; Ito, M.; Fujita, Y.; Ito, M.; Ichihara, M.; Masuda, A.; Suzuki, Y.; Maesawa, S.; Kajita, Y.; Hirayama, M.; et al. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson’s disease. Neurosci. Lett. 2009, 453, 81–85. [Google Scholar] [CrossRef]
  47. Fujita, K.; Seike, T.; Yutsudo, N.; Ohno, M.; Yamada, H.; Yamaguchi, H.; Sakumi, K.; Yamakawa, Y.; Kido, M.A.; Takaki, A.; et al. Hydrogen in Drinking Water Reduces Dopaminergic Neuronal Loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Parkinson’s Disease. PLoS ONE 2009, 4, e7247. [Google Scholar] [CrossRef]
  48. Li, J.; Wang, C.; Zhang, J.H.; Cai, J.-M.; Cao, Y.-P.; Sun, X.-J. Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimer’s disease by reduction of oxidative stress. Brain Res. 2010, 1328, 152–161. [Google Scholar] [CrossRef]
  49. Nishimaki, K.; Asada, T.; Ohsawa, I.; Nakajima, E.; Ikejima, C.; Yokota, T.; Kamimura, N.; Ohta, S. Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment. Curr. Alzheimer Res. 2018, 15, 482–492. [Google Scholar] [CrossRef]
  50. Ono, H.; Nishijima, Y.; Ohta, S. Therapeutic Inhalation of Hydrogen Gas for Alzheimer’s Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study. Pharmaceuticals 2023, 16, 434. [Google Scholar] [CrossRef] [PubMed]
  51. Ohno, K.; Hirayama, M.; Ito, M.; Minato, T.; Yoritaka, A.; LeBaron, T.W. Inhalation of hydrogen gas elevates urinary 8-hydroxy-2′-deoxyguanine in Parkinson’s disease. Med. Gas Res. 2019, 8, 144–149. [Google Scholar] [CrossRef] [PubMed]
  52. Yoritaka, A.; Ohtsuka, C.; Maeda, T.; Hirayama, M.; Abe, T.; Watanabe, H.; Saiki, H.; Oyama, G.; Fukae, J.; Shimo, Y.; et al. Randomized, double-blind, multicenter trial of hydrogen water for Parkinson’s disease. Mov. Disord. 2018, 3, 1505–1507. [Google Scholar] [CrossRef] [PubMed]
  53. Hong, C.-T.; Hu, C.-J.; Lin, H.-Y.; Wu, D. Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease: A pilot study. Medicine 2021, 100, e24191. [Google Scholar] [CrossRef] [PubMed]
  54. Yoritaka, A.; Takanashi, M.; Hirayama, M.; Nakahara, T.; Ohta, S.; Hattori, N. Pilot study of H2 therapy in Parkinson’s disease: A randomized double-blind placebo-controlled trial. Mov. Disord. 2013, 28, 836–839. [Google Scholar] [CrossRef] [PubMed]
  55. Guan, W.-J.; Wei, C.-H.; Chen, A.-L.; Sun, X.-C.; Guo, G.-Y.; Zou, X.; Shi, J.-D.; Lai, P.-Z.; Zheng, Z.-G.; Zhong, N.-S. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial. J. Thorac. Dis. 2020, 12, 3448–3452. [Google Scholar] [CrossRef]
  56. China National Health Commision, 04.03.20. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th Edition). Available online: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html (accessed on 30 September 2023).
  57. Botek, M.; Krejčí, J.; Valenta, M.; McKune, A.; Sládečková, B.; Konečný, P.; Klimešová, I.; Pastucha, D. Molecular Hydrogen Positively Affects Physical and Respiratory Function in Acute Post-COVID-19 Patients: A New Perspective in Rehabilitation. Int. J. Environ. Res. Public Health 2022, 19, 1992. [Google Scholar] [CrossRef]
  58. Luo, P.; Ding, Y.; He, Y.; Chen, D.; He, Q.; Huang, Z.; Huang, S.; Lei, W. Hydrogen-oxygen therapy alleviates clinical symptoms in twelve patients hospitalized with COVID-19: A retrospective study of medical records. Medicine 2022, 101, e27759. [Google Scholar] [CrossRef]
  59. Matsuura, H.; Matsumoto, H.; Okuzaki, D.; Shimizu, K.; Ogura, H.; Ebihara, T.; Matsubara, T.; Hirano, S.-I.; Shimazu, T. Hydrogen Gas Therapy Attenuates Inflammatory Pathway Signaling in Septic Mice. J. Surg. Res. 2021, 263, 63–70. [Google Scholar] [CrossRef] [PubMed]
  60. Xie, K.; Wang, Y.; Yin, L.; Wang, Y.; Chen, H.; Mao, X.; Wang, G. Hydrogen Gas Alleviates Sepsis-Induced Brain Injury by Improving Mitochondrial Biogenesis Through the Activation of PGC-α in Mice. Shock 2021, 55, 100–109. [Google Scholar] [CrossRef] [PubMed]
  61. Kasuyama, K.; Tomofuji, T.; Ekuni, D.; Tamaki, N.; Azuma, T.; Irie, K.; Endo, Y.; Morita, M. Hydrogen-rich water attenuates experimental periodontitis in a rat model. J. Clin. Periodontol. 2011, 38, 1085–1090. [Google Scholar] [CrossRef]
  62. Xia, C.; Liu, W.; Zeng, D.; Zhu, L.; Sun, X.; Sun, X. Effect of Hydrogen-Rich Water on Oxidative Stress, Liver Function, and Viral Load in Patients with Chronic Hepatitis B. Clin. Transl. Sci. 2013, 6, 372–375. [Google Scholar] [CrossRef] [PubMed]
  63. Aoki, K.; Nakao, A.; Adachi, T.; Matsui, Y.; Miyakawa, S. Pilot study: Effects of drinking hydrogen-rich water on muscle fatigue caused by acute exercise in elite athletes. Med. Gas Res. 2012, 2, 12. [Google Scholar] [CrossRef]
  64. Da Ponte, A.; Giovanelli, N.; Nigris, D.; Lazzer, S. Effects of hydrogen rich water on prolonged intermittent exercise. J. Sports Med. Phys. Fit. 2018, 58, 612–621. [Google Scholar] [CrossRef]
  65. Javorac, D.; Stajer, V.; Ratgeber, L.; Betlehem, J.; Ostojic, S. Short-term H2 inhalation improves running performance and torso strength in healthy adults. Biol. Sport 2019, 36, 333–339. [Google Scholar] [CrossRef]
  66. Koyama, K.; Dobashi, S.; Takeuchi, K. Hydrogen-rich water suppresses the reduction in blood total antioxidant capacity induced by 3 consecutive days of severe exercise in physically active males. Med. Gas Res. 2020, 10, 21–26. [Google Scholar] [CrossRef] [PubMed]
  67. Mikami, T.; Tano, K.; Lee, H.; Lee, H.; Park, J.; Ohta, F.; LeBaron, T.W.; Ohta, S. Drinking hydrogen water enhances endurance and relieves psychometric fatigue: A randomized, double-blind, placebo-controlled study. Can. J. Physiol. Pharmacol. 2019, 97, 857–862. [Google Scholar] [CrossRef]
  68. Ostojic, S.M.; Vukomanovic, B.; Calleja-Gonzalez, J.; Hoffman, J.R. Effectiveness of Oral and Topical Hydrogen for Sports-Related Soft Tissue Injuries. Postgrad. Med. 2014, 126, 188–196. [Google Scholar] [CrossRef] [PubMed]
  69. Korovljev, D.; Trivic, T.; Drid, P.; Ostojic, S.M. Molecular hydrogen affects body composition, metabolic profiles, and mitochondrial function in middle-aged overweight women. Ir. J. Med. Sci. 2018, 187, 85–89. [Google Scholar] [CrossRef] [PubMed]
  70. Kajiyama, S.; Hasegawa, G.; Asano, M.; Hosoda, H.; Fukui, M.; Nakamura, N.; Kitawaki, J.; Imai, S.; Nakano, K.; Ohta, M.; et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr. Res. 2008, 28, 137–143. [Google Scholar] [CrossRef]
  71. Nakao, A.; Toyoda, Y.; Sharma, P.; Evans, M.; Guthrie, N. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. J. Clin. Biochem. Nutr. 2010, 46, 140–149. [Google Scholar] [CrossRef] [PubMed]
  72. Song, G.; Li, M.; Sang, H.; Zhang, L.; Li, X.; Yao, S.; Yu, Y.; Zong, C.; Xue, Y.; Qin, S. Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. J. Lipid Res. 2013, 54, 1884–1893. [Google Scholar] [CrossRef] [PubMed]
  73. LeBaron, T.W.; Singh, R.B.; Fatima, G.; Kartikey, K.; Sharma, J.P.; Ostojic, S.M.; Gvozdjakova, A.; Kura, B.; Noda, M.; Mojto, V.; et al. The effects of 24-week, high-concentration hydrogen-rich water on body composition, blood lipid profiles and inflammation biomarkers in men and women with metabolic syndrome: A randomized controlled trial. Diabetes Metab Syndr Obes. 2020, 13, 889–896. [Google Scholar] [CrossRef]
  74. Todorovic, N.; Fernández-Landa, J.; Santibañez, A.; Kura, B.; Stajer, V.; Korovljev, D.; Ostojic, S.M. The Effects of Hydrogen-Rich Water on Blood Lipid Profiles in Clinical Populations: A Systematic Review and Meta-Analysis. Pharmaceuticals 2023, 16, 142. [Google Scholar] [CrossRef]
  75. Ishibashi, T.; Sato, B.; Rikitake, M.; Seo, T.; Kurokawa, R.; Hara, Y.; Naritomi, Y.; Hara, H.; Nagao, T. Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis: An open-label pilot study. Med. Gas Res. 2012, 2, 27. [Google Scholar] [CrossRef]
  76. Ishibashi, T.; Sato, B.; Shibata, S.; Sakai, T.; Hara, Y.; Naritomi, Y.; Koyanagi, S.; Hara, H.; Nagao, T. Therapeutic efficacy of infused molecular hydrogen in saline on rheumatoid arthritis: A randomized, double-blind, placebo-controlled pilot study. Int. Immunopharmacol. 2014, 21, 468–473. [Google Scholar] [CrossRef]
  77. Qian, L.; Liu, M.; Shen, J.; Cen, J.; Zhao, D. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial. Front. Immunol. 2020, 11, 598359. [Google Scholar] [CrossRef]
  78. Korovljev, D.; Stajer, V.; Ostojic, J.; LeBaron, T.W.; Ostojic, S.M. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: A randomized controlled pilot trial. Clin. Res. Hepatol. Gastroenterol. 2019, 43, 688–693. [Google Scholar] [CrossRef] [PubMed]
  79. Kura, B.; Szantova, M.; LeBaron, T.W.; Mojto, V.; Barancik, M.; Bacova, B.S.; Kalocayova, B.; Sykora, M.; Okruhlicova, L.; Tribulova, N.; et al. Biological Effects of Hydrogen Water on Subjects with NAFLD: A Randomized, Placebo-Controlled Trial. Antioxidants 2022, 11, 1935. [Google Scholar] [CrossRef] [PubMed]
  80. Tao, G.; Zhang, G.; Chen, W.; Yang, C.; Xue, Y.; Song, G.; Qin, S. A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease. J. Cell. Mol. Med. 2022, 26, 4113–4123. [Google Scholar] [CrossRef] [PubMed]
  81. Igarashi, T.; Ohsawa, I.; Kobayashi, M.; Umemoto, Y.; Arima, T.; Suzuki, H.; Igarashi, T.; Otsuka, T.; Takahashi, H. Effects of hydrogen in prevention of corneal endothelial damage during phacoemulsification: A prospective randomized clinical trial. Am. J. Ophthalmol. 2019, 207, 10–17. [Google Scholar] [CrossRef] [PubMed]
  82. Nakayama, M.; Nakano, H.; Hamada, H.; Itami, N.; Nakazawa, R.; Ito, S. A novel bioactive haemodialysis system using dissolved dihydrogen (H2) produced by water electrolysis: A clinical trial. Nephrol. Dial. Transplant. 2010, 25, 3026–3033. [Google Scholar] [CrossRef] [PubMed]
  83. Nakayama, M.; Itami, N.; Suzuki, H.; Hamada, H.; Yamamoto, R.; Tsunoda, K.; Osaka, N.; Nakano, H.; Maruyama, Y.; Kabayama, S.; et al. Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study. Sci. Rep. 2018, 8, 254. [Google Scholar] [CrossRef]
  84. Ono, H.; Nishijima, Y.; Adachi, N.; Sakamoto, M.; Kudo, Y.; Nakazawa, J.; Kaneko, K.; Nakao, A. Hydrogen(H2) treatment for acute erythymatous skin diseases. A report of 4 patients with safety data and a non-controlled feasibility study with H2 concentration measurement on two volunteers. Med. Gas Res. 2012, 2, 14. [Google Scholar] [CrossRef]
  85. Matsumoto, S.; Ueda, T.; Kakizaki, H. Effect of Supplementation With Hydrogen-rich Water in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Urology 2013, 81, 226–230. [Google Scholar] [CrossRef]
  86. Ito, M.; Ibi, T.; Sahashi, K.; Ichihara, M.; Ito, M.; Ohno, K. Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies. Med. Gas Res. 2011, 1, 24. [Google Scholar] [CrossRef]
  87. Zhou, G.; Goshi, E.; He, Q. Micro/Nanomaterials-Augmented Hydrogen Therapy. Adv. Health Mater. 2019, 8, e1900463. [Google Scholar] [CrossRef]
  88. Zhang, L.; Yu, H.; Tu, Q.; He, Q.; Huang, N. New Approaches for Hydrogen Therapy of Various Diseases. Curr. Pharm. Des. 2021, 27, 636–649. [Google Scholar] [CrossRef] [PubMed]
  89. Wan, W.-L.; Lin, Y.-J.; Shih, P.-C.; Bow, Y.-R.; Cui, Q.; Chang, Y.; Chia, W.-T.; Sung, H.-W. An In Situ Depot for Continuous Evolution of Gaseous H2 Mediated by a Magnesium Passivation/Activation Cycle for Treating Osteoarthritis. Angew. Chem. Int. Ed. 2018, 57, 9875–9879. [Google Scholar] [CrossRef]
  90. Liu, J.; Wang, H.; Yuan, Q.; Song, X. A novel material of nanoporous magnesium for hydrogen generation with salt water. J. Power Sources 2018, 395, 8–15. [Google Scholar] [CrossRef]
  91. Fan, M.; Wen, Y.; Ye, D.; Jin, Z.; Zhao, P.; Chen, D.; Lu, X.; He, Q. Acid-Responsive H2-Releasing 2D MgB2Nanosheet for Therapeutic Synergy and Side Effect Attenuation of Gastric Cancer Chemotherapy. Adv. Healthc. Mater. 2019, 8, 1900157. [Google Scholar] [CrossRef] [PubMed]
  92. Kamimura, N.; Ichimiya, H.; Iuchi, K.; Ohta, S. Molecular hydrogen stimulates the gene expression of transcriptional coactivator PGC-1α to enhance fatty acid metabolism. NPJ Aging Mech. Dis. 2016, 2, 16008. [Google Scholar] [CrossRef] [PubMed]
  93. Li, Y.; Li, L.; Wang, S.; Liu, Y.; Zou, J.; Ding, W.; Du, H.; Shen, W. Magnesium hydride acts as a convenient hydrogen supply to prolong the vase life of cut roses by modulating nitric oxide synthesis. Postharvest Biol. Technol. 2021, 177, 111526. [Google Scholar] [CrossRef]
  94. Johnsen, H.M.; Filtvedt, W.; Hiorth, M.; Klaveness, J. Silicon nanoparticles for oral administration of molecular hydrogen. Int. J. Pharm. 2022, 629, 122371. [Google Scholar] [CrossRef]
  95. Shimada, M.; Koyama, Y.; Kobayashi, Y.; Kobayashi, H.; Shimada, S. Effect of the new silicon-based agent on the symptoms of interstitial pneumonitis. Sci. Rep. 2023, 13, 5707. [Google Scholar] [CrossRef] [PubMed]
  96. Kawamura, M.; Imamura, R.; Kobayashi, Y.; Taniguchi, A.; Nakazawa, S.; Kato, T.; Namba-Hamano, T.; Abe, T.; Uemura, M.; Kobayashi, H.; et al. Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method. Front. Med. 2020, 7, 95. [Google Scholar] [CrossRef]
  97. Kobayashi, Y.; Imamura, R.; Koyama, Y.; Kondo, M.; Kobayashi, H.; Nonomura, N.; Shimada, S. Renoprotective and neuroprotective effects of enteric hydrogen generation from Si-based agent. Sci. Rep. 2020, 10, 5859. [Google Scholar] [CrossRef]
  98. Wang, X.; Tong, B.; Hui, R.; Hou, C.; Zhang, Z.; Zhang, L.; Xie, B.; Ni, Z.; Cong, B.; Ma, C.; et al. The role of hyperthermia in methamphetamine-induced 971 depression-like behaviors: Protective effects of coral calcium hydride. Front. Mol. Neurosci. 2022, 14, 808807. [Google Scholar] [CrossRef] [PubMed]
Molecules 28 07785 g001
Figure 1. The number of clinical trials and scientific publications about hydrogen therapy in humans, sorted after publication year from 2010 to 2023 (per August 2023).
Figure 1. The number of clinical trials and scientific publications about hydrogen therapy in humans, sorted after publication year from 2010 to 2023 (per August 2023).
Molecules 28 07785 g001
Molecules 28 07785 g002
Figure 2. Registered clinical trials (t) and scientific publications (p) about hydrogen therapy, sorted by disease indication and administration method.
Figure 2. Registered clinical trials (t) and scientific publications (p) about hydrogen therapy, sorted by disease indication and administration method.
Molecules 28 07785 g002
Molecules 28 07785 g004
Figure 4. Trial overview and results from a successful COVID-19 study, showing all end-point parameters were positive after H2-O2 inhalation compared to control. * p < 0.05, ** p < 0.01, EOT = end-of-treatment. Reproduced with permission from [55], Journal of Thoracic Disease; published by AME Publishing Company, Hong Kong, 2020.
Figure 4. Trial overview and results from a successful COVID-19 study, showing all end-point parameters were positive after H2-O2 inhalation compared to control. * p < 0.05, ** p < 0.01, EOT = end-of-treatment. Reproduced with permission from [55], Journal of Thoracic Disease; published by AME Publishing Company, Hong Kong, 2020.
Molecules 28 07785 g004
Table 1. Clinical trials studying the safety and therapeutic effects of H2 administration registered at clinicaltrials.gov, outlining disease studied, administration method, trial status, the date the trial was first submitted and location. NA = not applicable.
Table 1. Clinical trials studying the safety and therapeutic effects of H2 administration registered at clinicaltrials.gov, outlining disease studied, administration method, trial status, the date the trial was first submitted and location. NA = not applicable.
NCT No.Indication/Condition/DiseaseAdministration MethodPhase/StatusDate First Posted/Location
COVID-19
04594460Convalescent COVID-19Hydrogen-oxygen mixed gas inhalation (2:1, H2:O2)NA/ Not yet recruitingOctober 2020/China
04378712COVID-19Hydrogen-oxygen mixed gas inhalation (2:1, H2:O2)NA/CompletedMay 2020/China
04336462COVID-19Hydrogen-oxygen mixed gas inhalation (2:1, H2:O2)NA/RecruitingApril 2020/China
05504460Discharged patients previously hospitalized for COVID-19 pneumoniaHydrogen-Oxygen Generator with Nebulizer (inhalation)NA/RecruitingAugust 2022/China
05539664COVID-19Hydrogen-Oxygen Generator with Nebulizer (inhalation)NA/Active, not recruitingAugust 2022/China
05770206COVID-19Hydrogen-Oxygen Generator with Nebulizer (inhalation)NA/Not yet recruitingFebruary 2023/China
04633980Moderate COVID-19Inhalation of hydrogen gas 3.6% in N21/Not yet recruitingNovember 2020/France
04716985COVID-19 Patients Treated in Ambulatory CareHydrogen-rich water, oral (from dissolved 80 mg magnesium in water), 0.5 L/dayNA/RecruitingJanuary 2021/Serbia, France and Morocco
Lifestyle-related and exercise
03846141Health and Exercise Performance (HIHEP)Hydrogen inhalation, 4%NA/CompletedFebruary 2019/Serbia
05842993Diabetes type 2Hydrogen inhalation, 2 L/minNA/RecruitingApril 2023/China
05905588Diabetes type 2Hydrogen-rich water, oralNA/RecruitingMay 2023/China
05799911Exercise performance in professional athletesHydrogen-rich water, oral (1–3 L/day)NA/CompletedMarch 2023/Czechia
05862987Acute Body Response and Recovery After 5 km RunHydrogen-rich water, oralNA/Enrolling by invitationMay 2023/Czechia
02832219Metabolic fitness in obesityHydrogen tablet, oral3/CompletedJuly 2016/Serbia
01759498Sport-related Soft Tissue InjuriesOral hydrogen-rich capsules and/or topical hydrogen-rick packs2/CompletedJanuary 2013/Serbia
04167202Acute Ankle SprainAnkle baths with hydrogen-rich waterNA/CompletedNovember 2019/Serbia
Cancer
03818347Cancer rehabilitationHydrogen-oxygen mixed gas inhalation (2:1, H2:O2, 3 L/min)NA/CompletedJanuary 2019/China
05728112Head and Neck Cancer, Fatigue, Pain and Quality of LifeHydrogen inhalationNA/RecruitingJanuary 2023/Taiwan
04175301Concurrent radiotherapy and chemotherapy for High Grade Glioma patientsHydrogen-rich water, oral (from dissolved 80 mg magnesium in water)2/RecruitingNovember 2019/NY USA
04713332Radiation-Induced Adverse Events, Rectal CancerHydrogen-rich water, oral (comparing to vitamin E)3/RecruitingJanuary 2021/Jordan
05913895Oral Mucositis after Therapy (radiation or combined chemo) in Head and Neck Cancer patientsHydrogen-rich water, oralNA/Not yet recruitingJune 2023/Taiwan
05278260Mucositis from Radiation Therapy in Head and Neck Cancer PatientsHydrogen-rich water, oralNA/recruitingMarch 2022/NY USA
Respiratory
04000451Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Hydrogen-oxygen mixed gas inhalation (2:1, H2:O2)NA/CompletedJune 2019/China
02765295BronchiectasisHydrogen-oxygen mixed gas inhalation (2:1, H2:O2)NA/RecruitingMay 2016/China
02850185Severe COPD PatientsHydrogen-oxygen mixed gas inhalation (2:1, H2:O2), adjuvant therapyNA/RecrutitingJuly 2016/China
02883582Severe AsthmaHydrogen-oxygen mixed gas inhalation (2:1, H2:O2)NA/UnknownAugust 2016/China
02961387Dyspnea in patients with Tracheal StenosisInhalation of hydrogen gas.NA/UnknownNovember 2016/China
CNS and cognitive
02830854Cognitive Function and Performance in ElderlyHydrogen inhalation 3%3/CompletedJuly 2016/Serbia
05891938Alzheimer’s diseaseHydrogen inhalationNA/CompletedMay 2023/Korea
03971617Parkinson’s diseaseHydrogen-rich water, oral (from dissolved 80 mg magnesium in water)2 and 3/RecruitingJune 2019/NY USA
03320018Acute Ischemic StrokeOral or IV H2 rich solution combined with oral or IV administration of minocycline2 and 3/UnknownOctober 2017/NY USA
Autoimmune
05116215Autoimmune disease, rheumatologic patientsEither H2 capsules, oral, H2 inhalation 2% or H2-rich water, oral, with conventional treatment1/RecruitingOctober 2021/Taiwan
02918188Chronic graft-versus-host diseaseHydrogen-rich water, oral2/RecruitingSeptember 2016/China
05196295Rheumatologic and Metabolic PatientsHydrogen capsules, oral1 /RecruitingJanuary 2022/Taiwan
Cardiovascular
05282836Aneurysmal Subarachnoid Hemorrhage (HOMA)Hydrogen-oxygen mixed gas inhalation (2:1, H2:O2, 3 L/min)NA/Not yet recruitingAugust 2022/China
05574296Cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR)Hydrogen gas inhalation 2.4% in medical air1/Not yet recruitingOctober 2022/MA USA
Liver
05325398Non-Alcoholic Fatty Liver diseaseHydrogen-rich water, oralNA/CompletedMay 2021/Slovakia
03625362Non-Alcoholic Fatty Liver diseaseHydrogen-rich water, oralNA/CompletedAugust 2018/Serbia
Fatigue
05013606Chronic Fatigue SyndromeHydrogen-rich water, oralNA/CompletedFebruary 2019/NY USA
05397626Chronic Fatigue SyndromeHydrogen-rich water, oral, with or without HRV-BF (biofeedback)1/RecruitingMay 2021/NY USA
Other
05248360InsomniaHydrogen-oxygen mixed gas inhalation (2:1, H2:O2, 900 mL/min)NA/Enrolling by invitationFebruary 2022/China
05476575Post-operative Pain and Inflammation Cytokines4% Hydrogen inhalation via nasal cannula perioperativelyNA/RecruitingOctober 2021/Taiwan
04046211Safety of Inhaled Hydrogen Gas Mixtures in Healthy VolunteersHydrogen gas inhalation 2.4% in medical air1/CompletedAugust 2019/MA USA
04881435Sudden Sensorineural Hearing LossHydrogen gas inhalation with standard steroid treatmentNA/Unknown statusMay 2021/Taiwan
04430803AgingHydrogen-rich water, oralNA/Active, not recruitingJune 2020/Serbia
05556252Premenstrual Symptoms and Quality of Life in students with premenstrual syndromeHydrogen-rich water, oralNA/CompletedSeptember 2022/Turkey
02613195Aging grafts in (DBD) liver/kidney transplantation (HRCSDBD)Hydrogen bath, liver grafts lavaged and cold stored with hydrogen-rich Celsior solution3/UnknownNovember 2015/China
Table 2. Clinical trials studying safety and therapeutic effects of H2 administration conducted in Japan and registered at umin.ac.jp/ctr, outlining disease studied, administration method and the date of disclosure of the study information.
Table 2. Clinical trials studying safety and therapeutic effects of H2 administration conducted in Japan and registered at umin.ac.jp/ctr, outlining disease studied, administration method and the date of disclosure of the study information.
UMIN IDIndication/Disease/EffectsAdministration MethodDate Posted
Lifestyle-related and exercise
000023116Body fat-reducing, anti-oxidant and anti-fatigueHydrogen-rich water, oralDecember 2017
000029322Pre-metabolic syndromeHydrogen-rich water, oralSeptember 2017
000029321Metabolic syndromeHydrogen-rich water, oralSeptember 2017
000019032Type 2 diabetesHydrogen-rich water, oralOctober 2015
000018182Type 2 diabetesHydrogen-rich water, oralJuly 2015
000029062Exercise tolerance and fatigueHydrogen-rich water, oralSeptember 2017
000050872Anti-fatigue during exerciseHydrogen-rich water, oralApril 2023
Cancer
000035864Side effect in cancer patients receiving radiotherapyHydrogen gas inhalation February 2019
CNS and cognitive
000019820Neurological outcome following brain ischemia during post-cardiac arrest care2% hydrogen gas inhalationJanuary 2016
000019082Parkinson’s disease 3.5% hydrogen gas inhalationSeptember 2015
000010014Parkinson’s diseaseHydrogen-rich water, oralFebruary 2013
000007497Parkinson’s diseaseHydrogen-rich water, oralMarch 2012
000008959Multiple system atrophy and Progressive supranuclear palsyHydrogen-rich water, oralOctober 2012
Cardiovascular
000014630Ischemia-reperfusion after lung transplantation1.3% hydrogen gas inhalationAugust 2014
000014390Acute myocardial infarctionHydrogen gas inhalationJuly 2014
000032523Peripheral endothelial functionHydrogen-rich water, oralMay 2018
000032510Peripheral endothelial functionHydrogen-rich water, oralMay 2018
000033459Peripheral endothelial functionHydrogen-rich water, oralJuly 2018
000032701Cardiovascular diseasesHydrogen tablet, oral May 2019
000021154HypertensionHydrogen tablet, oral February 2016
Liver
000010693Chronic hepatitis and liver cirrhosisHydrogen-rich water, oralMay 2013
Fatigue
000027700Anti-fatigueHydrogen-rich water, oralNovember 2018
Safety and distribution
000023550H2 concentrations in expired air after intake of hydrogen-rich water and water containing indigestible sugarsHydrogen-rich water, oralAugust 2016
000037169Change in H2 concentration in breath by H2 supplementationHydrogen-rich water, oralJune 2019
000036250Change in H2 concentration in breath by H2 supplementationHydrogen-rich water, oralMarch 2019
000013221Safety of hydrogen eye dropHydrogen eye dropFebruary 2014
Physiological/molecular markers
000051588Effects of hydrogen gas inhalation on oxidized lipidsHydrogen gas inhalation by nasal inhalerJuly 2023
000005779Detection of reduction in oxidative stressHydrogen-rich water, oralSeptember 2011
000039708Effects of H2 on the cytokine and oxidative stress levels in pregnant womenHydrogen-rich water, oralApril 2020
000019654Effects of H2 water on gut peptideHydrogen-rich water, oralNovember 2015
000033102Effects of H2 water on gut microbiotaHydrogen-rich water, oralJune 2018
Other
000033110Pain/swelling of the hands and armsHydrogen-rich water bath June 2018
000015528Ischemia-reperfusion injury of retinal artery occlusionHydrogen-rich eye dropOctober 2014
000045459Systemic inflammatory reaction syndromeInjection of H2-rich water using a catheter-tipped syringe directly from the gastric tubeSeptember 2021
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Johnsen, H.M.; Hiorth, M.; Klaveness, J. Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes. Molecules 2023, 28, 7785. https://doi.org/10.3390/molecules28237785

AMA Style

Johnsen HM, Hiorth M, Klaveness J. Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes. Molecules. 2023; 28(23):7785. https://doi.org/10.3390/molecules28237785

Chicago/Turabian Style

Johnsen, Hennie Marie, Marianne Hiorth, and Jo Klaveness. 2023. "Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes" Molecules 28, no. 23: 7785. https://doi.org/10.3390/molecules28237785

APA Style

Johnsen, H. M., Hiorth, M., & Klaveness, J. (2023). Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes. Molecules, 28(23), 7785. https://doi.org/10.3390/molecules28237785

Article Metrics

Back to TopTop